Kamada Ltd. · NASDAQ:KMDA
Kamada — Investor Presentation (January 2025)
24 slides from Kamada's investor presentation, Jan 8, 2025
Slide 1: Corporate Presentation January 2025
Corporate Presentation January 2025 PRO F ITABLE GROWTH THROUGH SPECIALTY PLASMA THERAPIES NASDAQ: KMDA; TASE: KMDA.TA
Slide 2: Forward-Looking Statement
FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials
Slide 3: Kamada - A Global Biopharmaceutical Company
KEDRAB® CYTOGAM ® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GLOBAL BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 15 % CAGR (from 2021) $ 178 - 182M 1 2025 Revenues Guidance $ 38 - 42M 1 2025 Adj. EBIDTA Guidance 4 Pillars of Growth A LEADER IN SPECIALTY PLASMA THERAPIES, WITH A PORTFOLIO
Slide 4: What Makes Us Unique
Multi - scale Innovative Agile WHAT MAKES US UNIQUE First to develop an FDA - approved liquid - ready - to - use IV AAT therapy First to advance an Inhaled AAT therapy to a pivotal phase III study First to demonstrate safety and efficacy of anti - Rabies IgG in pediatric population First to treat CO
Slide 5: Global Commercial Footprint
GLOBAL COMMERCIAL FOOTPRINT United States El Salvador Brazil Nigeria India South Korea Russia Israel Chile Thailand Sri Lanka Australia South Africa Uruguay Argentina Paraguay Colombia Canada Hong Kong Saudi Arabia Kuwait Qatar Bahrain UAE Egypt Philippines Jordan Iraq Netherlands Montenegro Albania
Slide 6: Experienced Leadership
6 EXPERIENCED LEADERSHIP Amir London CEO Hanni Neheman VP Marketing & Sales Liron Reshef VP Human Resources Shavit Beladev VP Kamada Ɗ Plasma Chaime Orlev CFO Jon Knight VP U.S Commercial Yael Brenner VP Quality Boris Gorelik VP Business Development & Strategic Programs Nir Livneh VP Legal, General
Slide 7: Delivering on Our Commitments
DELIVERING ON OUR COMMITMENTS 7
Slide 8: Annual Double-Digit Growth Trajectory
6 18 24 32 - 35 38 - 42 2021 2022 2023 2024 2025 104 129 143 158 – 162 178 - 182 2021 2022 2023 2024 2025 ADJUSTED EBITDA US$M 61 % CAGR 2024 and 2025 represents annual guidance 2024 and 2025 represents annual guidance ANNUAL DOUBLE - DIGIT GROWTH TRAJECTORY REVENUES US$M 15 % CAGR 9 M $ 122 M ( 76
Slide 9: 9M-24 Continuing the Growth
GROSS MARGIN REVENUE 4% 9M/23 39% 9 M/ 24 43 % 15% 9M/23 $106.1 9 M/ 24 $ 121.9 Adj. EBITDA EPS 43% 9M/23 $17.7 9 M/ 24 $ 25.4 X3 9M/23 $0.06 9M/24 $0.18 9 M – 24 CONTINUING THE GROWTH DOUBLE DIGIT REVENUE AND PROFIT INCREASE 9 For reconciliation of Adjusted EBITDA please refer to slide 22
Slide 10: Kamada's Roadmap for Annual Double-Digit Growth
KAMADA ’ S ROADMAP FOR ANNUAL DOUBLE - DIGIT GROWTH 10 Organic Growth Portfolio of 6 FDA - approved products; Over 30 territories M&A Transactions Support growth through M&A transactions Plasma Collection Centers $ 8 M - $ 10 M of expected annual revenues from each new center at peak capacity Inhale
Slide 11: Years Growth Journey
5 YEARS GROWTH JOURNEY 2025 & Beyond ĎČĎđ M&A 2026 - 2028 Plasma Collection ĎČĎĕ ū ĎČĎĔ Inhaled AAT O rganic Ɗ Growth 11
Slide 12: A Global Leader in Anti-Rabies Immune Globulin (HRIG)
$ 150 M Total U.S HRIG market size, KEDRAB presents double - digit growth YoY. Only anti - Rabies IgG product with FDA approved label confirming safety and effectiveness in children KEDRAB /KAMRAB $ 180 M Guaranteed sales in the U.S. 2024 - 2027 Only 2 FDA approved products Leading HRIG in Canada, A
Slide 13: CYTOGAM CMV Immune Globulin
CYTOGAM is the only plasma - derived IgG approved in the U.S. and Canada for prophylaxis of CMV disease after Solid Organ Transplantation. CMV is the leading cause for organ rejection post - transplant CYTOGAM ĎČĎď - 2024 Product re - launch, working with U.S. KOLs to generate new clinical and medic
Slide 14: Distribution Segment Growth
DISTRIBUTION SEGMENT GROWTH More than 25 products exclusively licensed from leading international pharmaceutical companies, marketed in the Israeli market EXCLUSIVE DISTRIBUTOR IN ISRAEL FOR LEADING BIOPHARMACEUTICAL COMPANIES Key areas : plasma - derived, respiratory, rare diseases, infectious dise
Slide 15: M&A Transactions
15 M&A TRANSACTIONS AIMING TO SECURE NEW BUSINESS DEVELOPMENT AND M&A TRANSACTIONS DURING 2025 ; LEVERAGING OVERALL FINANCIAL STRENGTH AND COMMERCIAL INFRASTRUCTURE Exploring strategic business development opportunities to identify potential acquisition or in - licensing to accelerate long - term gr
Slide 16: Kamada Plasma Expanding Vertical Integration & Revenue Growth
16 KAMADA PLASMA EXPANDING VERTICAL INTEGRATION & REVENUE GROWTH Collecting hyper - immune plasma for our specialty IgG products and normal source plasma (NSP) to support revenue growth Recently opened a new plasma collection center in Houston, Texas ; planning to open another center in San Antonio,
Slide 17: Inhaled AAT Phase 3 Pivotal Study
$ 2 Billion A substantial market opportunity ( 2028 ) č Based on expected changes to the statistical analysis plan, intend to reduce the study sample size to approximately 180 patients, and conduct an interim futility analysis by the end of 2025 FDA recently reconfirmed overall study design, endorse
Slide 18: Inhaled AAT Phase 3 Pivotal Study Design
INHALED AAT PHASE 3 PIVOTAL STUDY Non - Invasive, at - home treatment. Expected better ease of use and quality of life for AATD patients than current IV SOC Most effective mode of treatment for delivering therapeutic quantities of AAT directly into the airways Studied in more than 200 individuals to
Slide 19: Delivering on Our Commitments
KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GLOBAL BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 15 % CAGR (from 2021) $ 178 - 182 M 1 2025 Revenues Guidance $ 38 - 42 M 1 2025 Adj. EBIDTA Guidance 4 Pillars of Growth DELIVERING ON OUR COMMITMENTS $ 78.0 M Unaudited Cash (D
Slide 20: Thank You
THANK YOU www.kamada.com NASDAQ: KMDA; TASE: KMDA.TA
Slide 21: Details
21 DETAILS FY 2023 Q3/23 Q3/24 9M/23 9 M/ 24 US $ M Driven by two key growth drivers, KEDRAB® & CYTOGAM® 115.5 31.4 37.1 86.4 110.0 PROPRIETARY 27.1 6.5 4.6 19.7 11.9 DISTRIBUTION 15% YoY increase; 9M revenues - 76% of mid - point annual guidance 142.5 37.9 41.7 106.1 121.9 TOTAL REVENUES 55.5 14.8
Slide 22: Non-IFRS Measures – Adjusted EBITDA
22 NON - IFRS MEASURES – ADJUSTED EBITDA FY 2023 Q 3 / 23 Q 3 / 24 9 M/ 23 9 M/ 24 US $ M 8.3 3.2 3.9 3.2 10.7 NET PROFIT 0.1 0.1 0.1 0.2 0.2 TAXES ON INCOME 1.0 1.3 1.8 3.4 5.3 REVALUATION OF ACQUISITION RELATED CONTINGENT CONSIDERATION 0.7 ( 0.2 ) ( 0.4 ) 0.5 ( 1.2 ) OTHER FINANCIAL EXPENSE, NET 7
Slide 23: FDA-Approved Specialty Plasma Products
23 6 FDA - APPROVED SPECIALTY PLASMA PRODUCTS KEDRAB® [Rabies Immune Globulin (Human)] Post exposure prophylaxis of rabies infection CYTOGAM® [Cytomegalovirus Immune Globulin (Human)] Prophylaxis of CMV disease associated with transplants HEPGAM B® [Hepatitis B Immune Globulin (Human)] Prevention of
Slide 24: Immune Globulin (IgG) Manufacturing
24 This Photo by Unknown Author is licensed under CC BY - NC - ND IMMUNE GLOBULIN (IgG) MANGUFACTURING 02 Plasma Screening: High Titer Antibodies 03 Plasma Fractionation Purification process: 01 Plasma Collection in the United States 04 Viral Inactivation and Reduction 05 Formulation and Final Filli